Neotiv’s core product, neotivCare, is a CE class I medical device digital-health app that delivers structured memory tests aimed at people with subjective cognitive decline. The software is designed to help relatives encourage medical visits and to assist clinicians in determining whether cognitive deterioration qualifies as mild cognitive impairment. Neotiv says its tools can help pick up Alzheimer’s earlier, supporting earlier access to care and potentially better outcomes as treatments emerge. The company was founded in 2017 as a spinout from Otto von Guericke University Magdeburg and maintains a scientific advisory board with experts from the German Center for Neurodegenerative Diseases, UCL and UC Berkeley. Neotiv plans to use fresh funding to grow German customer adoption, expand internationally, and deliver further software innovations. The article cites global disease estimates (about 32 million Alzheimer’s patients and a further 69 million in a prodromal phase) as the addressable need the company aims to serve. Neotiv develops mobile apps that measure the psychological effects of Alzheimer’s disease at early stages using memory tests validated in national and international scientific studies. The tests produce scores that indicate whether specific brain regions are functionally compromised, delivering a snapshot of a patient’s mental capacity and enabling long‑term, high‑frequency memory monitoring. That monitoring is intended to enable dynamic tailoring of preventative and therapeutic measures and to help health‑conscious individuals optimize lifestyle changes to reduce dementia risk. The apps are designed for private users, clinicians and drug developers, allowing doctors to detect changes and monitor treatment courses. Drug developers can use the app to improve pre‑selection of trial candidates and to obtain higher‑frequency monitoring of treatment effects. The company is led by CEO Dr. Chris Rehse and dementia researcher Prof. Emrah Düzel and recently secured seed funding from High‑Tech Gründerfonds (amount undisclosed) to support product launch and development.

Total raised

$10M

Funding rounds

2

Latest round

Series A

Latest activity

Nov 2022